Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 225,670 | 484,472 | 707,427 | 389,477 | 527,765 |
| Marketable Securities | 1,709,975 | 1,517,147 | 1,400,698 | 1,304,215 | 1,212,061 |
| Receivables | N/A | N/A | N/A | 200,000 | N/A |
| TOTAL | $1,943,891 | $2,010,407 | $2,119,624 | $1,908,078 | $1,760,586 |
| Non-Current Assets | |||||
| PPE Net | 138,542 | 143,031 | 147,253 | 151,945 | 156,122 |
| Investments And Advances | 0 | 11,216 | 0 | 1,973 | 0 |
| Intangibles | 0 | 0 | 2 | 16 | 30 |
| Other Non-Current Assets | 173,697 | 175,199 | 172,138 | 167,559 | 170,092 |
| TOTAL | $312,239 | $329,446 | $319,393 | $321,493 | $326,244 |
| Total Assets | $2,256,130 | $2,339,853 | $2,439,017 | $2,229,571 | $2,086,830 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 15,578 | 9,452 | 16,463 | 38,147 | 26,152 |
| Accrued Expenses | 48,042 | 92,337 | 77,639 | 45,773 | 66,581 |
| Other current liabilities | 4,824 | 4,824 | 4,824 | 5,141 | N/A |
| TOTAL | $89,810 | $127,823 | $118,990 | $108,791 | $111,234 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 4,483 | 4,759 | 4,072 | 4,105 | 3,500 |
| Other Non-Current Liabilities | 214,339 | 218,498 | 222,550 | 223,965 | 231,979 |
| TOTAL | $226,662 | $231,081 | $236,091 | $237,977 | $247,802 |
| Total Liabilities | $316,472 | $358,904 | $355,081 | $346,768 | $359,036 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 85,353 | 85,168 | 84,918 | 80,276 | 79,432 |
| Common Shares | 2,684 | 2,665 | 2,658 | 2,497 | 2,476 |
| Retained earnings | -1,328,641 | -1,242,699 | -1,116,291 | -999,700 | -1,089,047 |
| Other shareholders' equity | 10,503 | -2,941 | -1,614 | 1,851 | -6,860 |
| TOTAL | $1,939,658 | $1,980,949 | $2,083,936 | $1,882,803 | $1,727,794 |
| Total Liabilities And Equity | $2,256,130 | $2,339,853 | $2,439,017 | $2,229,571 | $2,086,830 |